Linopirdine
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Linopirdine is a putative cognition-enhancing drug with a novel mechanism of action. Linopirdine blocks the KCNQ2\3 heteromer M current with an IC50 of 2.4nM[1] disinhibiting acetylcholine release, and increasing hippocampal CA3-schaffer collateral mediated glutamate release onto CA1 pyramidal neurons.[2] In a murine model linopirdine is able to nearly completely reverse the senescence-related decline in cortical c-FOS, an effect which is blocked by atropine and MK-801, suggesting Linopirdine can compensate for the age related decline in acetylcholine release.[3] Linopirdine also blocks homomeric KCNQ1 and KCNQ4 voltage gated potassium channels which contribute to vascular tone with substantially less selectivity than KCNQ2/3.[1]
References
- ↑ 1.0 1.1 PMID 9694925 (PMID 9694925)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 22674722 (PMID 22674722)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 11378256 (PMID 11378256)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH